ArticleHuman reproduction (Oxford, England)2026
AMH regulates ovary size by counteracting the positive influence of clustered ovarian follicle growth.
Article in Human reproduction (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interfollicular communication among preovulatory follicles after luteinizing hormone signaling.Endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
study questionDoes anti-Müllerian hormone (AMH) influence preantral follicle development within a short range of AMH-secreting antral follicles? SUMMARY ANSWER: Immunization of sheep against AMH leads to increased follicle survival, specifically in regions close to small-medium antral follicles. WHAT IS KNOWN ALREADY: Serum AMH is known to inhibit the survival of immature ovarian follicles, but its biological role remains poorly understood. Mammalian ovaries contain many more developing ovarian follicles than are needed for ovulation, but how these systems operate remains unclear. STUDY DESIGN, SIZE, DURATION: Cross-sectional-control versus treatment studies examining the effects in the presence or absence of AMH. PARTICIPANTS/MATERIALS, SETTING,
methodsAnti-AMH immunization experiments were conducted in sheep followed by histological 2D and 3D tissue analysis. Microdialysis was conducted on ex vivo human and sheep ovaries. Live-imaging of a fluorogenic enzyme-responsive reagent was conducted on ex vivo mouse ovaries. Organ/follicle culture was conducted on Amh+/+ and Amh-/- ovary tissues to measure follicle activation and growth rates. MAIN RESULTS AND THE ROLE OF CHANCE: The likely site of action of AMH was shown to be ovarian stroma adjacent to large follicles as microdialysis determined that receptor-activating concentrations of AMH were only observed within a short range of the follicle. The AMH-activating enzymes were also shown to be primarily located in stroma using live-imaging of a fluorogenic enzyme-responsive reagent. Sheep were immunized against AMH protein to inhibit extracellular signalling and the ovaries were examined using 3-dimensional reconstructions of ovarian follicle positions. This showed that inhibition of AMH signalling caused an increase in preantral follicle survival, but almost entirely in proximity to large developing follicles. LARGE SCALE DATA: None. LIMITATIONS, REASONS FOR CAUTION: Limited studies were conducted on human tissue but the results concur with the sheep experiments. Sheep ovaries provide a useful large-animal model for comparative anatomy with humans but there will be interspecies differences. WIDER IMPLICATIONS OF THE
findingsThese results add to the evidence that small growing follicle survival is influenced by the proximity of large follicles. This has relevance for conditions where large follicles are lacking (e.g. primary ovary insufficiency) or where follicle growth is excessive (e.g. PCOS). STUDY FUNDING/COMPETING INTEREST(S): This research was funded by a Sir Charles Hercus Research Fellowship from the Health Research Council of New Zealand (grant number 18-027). The authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.